Feasibility of implementing multi-viral point-of-care testing in GP practices for high-risk patients with respiratory infections

Feasibility of implementing multi-viral point-of-care testing in GP practices for high-risk patients with respiratory infections - RespiCare

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00033192

Enrollment

1600

Registered

2023-12-07

Start date

2023-11-09

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Corona/Flu/RSV

Interventions

Group 1: Intervention group: GP practices receive an mPOCT device that can detect influenza A and B, RSV and corona. GPs should treat patients in the infection season with a standard examination proce

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Persons aged 65 years or older (with or without comorbidities), (2) Adult persons of any age with pre-existing conditions associated with a relative risk of > 2 for hospitalization or death, e.g. diabetes mellitus, chronic kidney disease, obesity (BMI = 40), COPD and CHD.

Exclusion criteria

Exclusion criteria: (1) Minors, (2) Persons with severe cognitive impairment, e.g. advanced dementia, (3) Refusal to participate in the study

Design outcomes

Primary

Measure	Time frame
Assessment of the feasibility of implementing mPOCT devices in GP practices and potential hurdles	—

Secondary

Measure	Time frame
Recording of the structural process in the practice (e.g., location of the device, handling of the approx. 30-minute waiting time until the test result, time of the discussion of findings with patients). Recording of characteristics (e.g., demographics, previous illnesses, severity of illness) that lead to patients having to wait in the practice during the approx. 30-minute waiting time for the test result or being sent home. Recording of possible differences between the IG and CG with regard to the therapies used by the practitioners (e.g., prescription of antibiotics or antiviral medication) as well as the use of further diagnostic measures (e.g. collection of laboratory values). As part of the follow-up, recording of possible differences between the IG and CG with regard to the length of symptoms and sick leave, adverse events, re-visit(s) to the same or other medical services (e.g., hospitalization).	—

Measure

Time frame

Recording of the structural process in the practice (e.g., location of the device, handling of the approx. 30-minute waiting time until the test result, time of the discussion of findings with patients). Recording of characteristics (e.g., demographics, previous illnesses, severity of illness) that lead to patients having to wait in the practice during the approx. 30-minute waiting time for the test result or being sent home. Recording of possible differences between the IG and CG with regard to the therapies used by the practitioners (e.g., prescription of antibiotics or antiviral medication) as well as the use of further diagnostic measures (e.g. collection of laboratory values). As part of the follow-up, recording of possible differences between the IG and CG with regard to the length of symptoms and sick leave, adverse events, re-visit(s) to the same or other medical services (e.g., hospitalization).

—

Countries

Germany

Contacts

Public ContactTobias Tuchscherer

Institut für Allgemeinmedizin, Universität Leipzig

tobias.Tuchscherer@medizin.uni-leipzig.de+4915202764062

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026